You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1154 Results
Document
Dec 2024
Drug
Other Name(s): Votrient®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pazopanib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pazopanib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Guidelines and Advice
Status: Current
Version: 2
Dec 2024
Drug
Other Name(s): Lynparza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
The Ontario Steering Committee for Cancer Drugs (OSCCD) was created in 2013 to enhance and support the administration of Ontario's cancer drug...
Document
Jan 2025
Document
Jan 2025
Drug
Other Name(s): Taxol®
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Gazyva®
Quick Link(s): Drug Monograph, Patient Info Sheet
May 2022
Document
Jan 2025

Pages